LAUSR

To describe reason for initiation, and evolution under isavuconazole (ISZ) a 2-year prospective and observational study was performed. Anonymized data collected during the first 3 months of treatment were indications of treatment, efficacy, overall survival, evolution of toxicity markers, and ISZ trough levels. Fifty-one (26 invasive aspergillosis, 16 prophylaxis, 9 mucormycosis) patients started on isavuconazole. Isavuconazole was initiated upfront in 12/51 cases, especially to avoid toxicities from other antifungals. As second-line therapy (39/51 patients), isavuconazole was mostly initiated after toxicities of the previous treatments (66.7%; 26/39 cases). An improvement in toxicity markers was reported in most patients. However, 5 patients experienced adverse events. The mean ISZ trough levels measured from 179 samples collected in 37 patients was 3.33 +/- 1.64 mg/L. The mean ISZ through levels was significantly lower (P = 0.003) in alloHSCT recipients (3.10 +/- 1.45 mg/L) than in other patients (3.76 +/- 1.88 mg/L) but still within the expected range of efficacy. After 12 weeks, the overall survival was 69.2% (n = 18/26) in the invasive aspergillosis intention to treat (ITT) group and 44.4% (n = 4/9) in the mucormycosis ITT group. After 2 years, the overall survival was respectively 46.2% (n = 12/26) and 33.3% (n = 3/9) in these 2 groups.